Navigation Links
PAREXEL Expands Global Clinical Logistics Capabilities
Date:6/19/2008

enue included in backlog; the Company's dependence on certain industries and clients; the Company's ability to win new business, manage growth and costs, and attract and retain employees; the Company's ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business; the impact on the Company's business of government regulation of the drug, medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks. Such factors and others are discussed more fully in the section entitled "Risk Factors" of the Company's Quarterly Report on Form 10-Q for the period ended March 31, 2008 as filed with the SEC on May 9, 2008, which "Risk Factors" discussion is incorporated by reference in this press release. The forward-looking statements included in this press release represent the Company's estimates as of the date of this release. The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing the Company's estimates or views as of any date subsequent to the date of this press release.

PAREXEL is a registered trademark of PAREXEL International Corporation, and Perceptive Informatics is a trademark of Perceptive Informatics, Inc. All other names or marks may be registered trademarks or trademarks of their respective business and are hereby acknowledged.

Contacts:

Jennifer Baird, Rebecca Passo

Senior Director of Public Relations SHIFT Communications

PAREXEL International Tel: +617-779-1817

Tel: +781-434-440
'/>"/>

SOURCE PAREXEL International Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. PAREXEL International to Present at Thomas Weisel Partners Healthcare Conference
2. Parexel Consulting Strengthens Good Manufacturing Practice Capabilities in Europe
3. PAREXEL International Completes Acquisition of APEX International Clinical Research Co., Ltd.
4. PAREXEL International Updates Financial Guidance in Conjunction with the Acquisition of APEX International Clinical Research Co., Ltd. and Other Factors
5. PAREXEL Announces Date of First Quarter Fiscal Year 2008 Earnings Release and Conference Call
6. PAREXEL Reports First Quarter Fiscal Year 2008 Financial Results
7. PAREXEL Appoints Charles A. Stevens as Vice President/General Manager of Health Policy and Strategic Reimbursement and Strengthens Capabilities
8. PAREXEL Announces Date of Second Quarter Fiscal Year 2008 Earnings Release and Conference Call
9. PAREXEL Names Biopharmaceutical Industry Executive Eduard E. Holdener to Board of Directors
10. PAREXEL Reports Second Quarter Fiscal Year 2008 Financial Results
11. PAREXEL International Announces 2-For-1 Stock Split
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... ... July 31, 2015 , ... R-Biopharm is ... of partially hydrolyzed gluten in foods, has been accepted by AOAC International as ... Hydrolyzed Gluten in Fermented Cereal-Based Products by R5 Competitive ELISA,” based on a ...
(Date:7/30/2015)... Mass. , July 30, 2015   ... solutions for the interpretation and analysis of genomic ... Matthew Fischer has joined the company as ... Photo - http://photos.prnewswire.com/prnh/20150730/250931 ... capabilities to integrate, interpret, analyze and explore complex ...
(Date:7/30/2015)... -- According to a new market research ... PKPD, Trial Design, Toxicity Prediction, In-house, Contract Service), by ... End Users - Global Forecast to 2020", published by ... 2,107.99 million by 2020 from USD 1,034.93 million in ... Browse more than 75 market ...
(Date:7/30/2015)... DIEGO, July 30, 2015   Senomyx , Inc. ... taste science technologies to discover, develop, and commercialize novel ... industries, today reported financial results for the second quarter ... of 2015, we remain on track to achieve our ... Chief Executive Officer of the Company. "Since our last ...
Breaking Biology Technology:RIDASCREEN® Competitve Gliadin Receives AOAC Official First Action Status 2GenoSpace Introduces Matthew Fischer as Vice President of Sales and Marketing 2Biosimulation Market Worth 2,107.99 Million USD by 2020 2Biosimulation Market Worth 2,107.99 Million USD by 2020 3Biosimulation Market Worth 2,107.99 Million USD by 2020 4SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 2SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 3SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 4SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 5SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 6SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 7SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 8SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 9
... 2011 Reportlinker.com announces that a ... in its catalogue: What,s ... and Other Biologics) 2011-2015 ... future of the pharmaceutical market will ...
... aid the fight of the deadly outbreak of E. ... at the University Medical Centre Hamburg-Eppendorf have released an ... data previously released and submitted to NCBI in the ... assembled using the latest ion semiconductor sequencing technology, there ...
... Asmacure Ltee, a clinical-stage biopharmaceutical company focused ... treatment of asthma and other inflammatory diseases, announced today ... officer.  With a solid foundation established at Asmacure, Mr. ... lead compound, a potential new treatment for asthma with ...
Cached Biology Technology:Reportlinker Adds What's Next in Biologics? (mAbs, rDNA, Interferons, and Other Biologics) 2011-2015 2Reportlinker Adds What's Next in Biologics? (mAbs, rDNA, Interferons, and Other Biologics) 2011-2015 3Reportlinker Adds What's Next in Biologics? (mAbs, rDNA, Interferons, and Other Biologics) 2011-2015 4Reportlinker Adds What's Next in Biologics? (mAbs, rDNA, Interferons, and Other Biologics) 2011-2015 5Reportlinker Adds What's Next in Biologics? (mAbs, rDNA, Interferons, and Other Biologics) 2011-2015 6Reportlinker Adds What's Next in Biologics? (mAbs, rDNA, Interferons, and Other Biologics) 2011-2015 7Further Analysis on Improved Genome Assembly Indicates the Outbreak E. coli has Complex Genetics With Resistance to at Least Eight Antibiotics 2Further Analysis on Improved Genome Assembly Indicates the Outbreak E. coli has Complex Genetics With Resistance to at Least Eight Antibiotics 3Asmacure Ltee Appoints Pharmaceutical and Biotechnology Industry Veteran Martin Driscoll as CEO 2Asmacure Ltee Appoints Pharmaceutical and Biotechnology Industry Veteran Martin Driscoll as CEO 3
(Date:7/27/2015)... , July 27, 2015   Zynx Health ... experience-based clinical improvement solutions, today announced that its ... now available on Android smartphones and tablets. With ... post-care organizations can use ZynxCarebook to securely exchange ... condition, streamline care transitions to other care settings, ...
(Date:7/21/2015)... Connecticut , July 21, 2015  NXT-ID, ... "Company"), a biometric authentication company focused on the ... Wocket® smart wallet, announces that it has filed ... System and Method. This invention ... not only authorizes an account, but also the ...
(Date:7/13/2015)... Jul. 13, 2015 NXT-ID, Inc. (NASDAQ: ... authentication company focused on the growing mobile commerce ... patent 62/188684 for BEHAVIORAL-DIRECTED AUTHENTIATION METHOD ... convenient and secure method to make payments.  With ... methods, introduced with its groundbreaking voice-direct payment patent ...
Breaking Biology News(10 mins):Zynx Health Adds Android Device Support to ZynxCarebook Solution 2Zynx Health Adds Android Device Support to ZynxCarebook Solution 3NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 2NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 3NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 4NXT-ID Patents Behavior-Directed Payments 2NXT-ID Patents Behavior-Directed Payments 3NXT-ID Patents Behavior-Directed Payments 4
... to hear relies on hair cells, sensory receptors that mechanically ... transduction channel. Although the transduction channel was characterized more than ... molecular components. A new study in The Journal ... definitive identification of this mystery channel. Recent studies ...
... a long and complex process. Candidate drugs are evaluated ... of animals, usually rats or mice. Each class of ... often in a labor-intensive process that leaves plenty of ... consensus that current procedures fail to effectively produce new ...
... Clinical Practice Guideline (CPG) for the diagnosis and treatment ... in women of reproductive age and a leading cause ... of Polycystic Ovary Syndrome: An Endocrine Society Clinical Practice ... the Journal of Clinical Endocrinology and Metabolism ...
Cached Biology News:Finding psychiatric drugs in the movements of mice 2Finding psychiatric drugs in the movements of mice 3Experts clarify conflicting criteria for diagnosing polycystic ovary syndrome 2
Rabbit polyclonal to Glutathione S Transferase alpha ( Abpromise for all tested applications). Antigen: Full length protein: Human Glutathione S Transferase alpha. Entrez GeneID: 2938 Swi...
Affinity Purified Rabbit Anti-mouse sRANKL Biotinylated Polyclonal Antibody...
Mouse anti-IkBa/MAD-3 Class: Antibody Product Group: Signalling molecules and phospho-specific Antibody...
Mouse monoclonal [002-49] to C1s ( Abpromise for all tested applications). entrezGeneID: 716 SwissProtID: P09871...
Biology Products: